Deconstructing Williamsburg: Using focus groups to examine residents' perceptions of the building of a walkable community

<p>Abstract</p> <p>Background</p> <p>Components of the built environment are associated with active living behaviors, but research in this area has employed surveys and other quantitative methods almost exclusively. Qualitative approaches can provide additional detail about how neighborhoods influence physical activity, including informing the extent to which such relationships are causal in nature. The purpose of this study was to gain an in-depth understanding of residents' attitudinal and behavioral responses to living in a neighborhood designed to be walkable.</p> <p>Methods</p> <p>Focus groups were conducted with residents of a planned retail and residential development that was designed to embody many attributes of walkability and was located within a large city in southwestern Ontario. In total, 31 participants provided qualitative data about neighborhood resources and dynamics, use of local services, physical activity behavior, and other related issues. The data were transcribed and coded for themes relevant to the study purpose.</p> <p>Results</p> <p>Salient themes that emerged emphasized the importance of land use diversity, safety, parks and trails, aesthetics, and a sense of community, with the latter theme cutting across all others. The data also revealed mechanisms that explain relationships between the built environment and behavior and how sidewalks in the neighborhood facilitated diverse health behaviors and outcomes. Finally, residents recited several examples of changes in behavior, both positive and negative, since moving to their current neighborhood.</p> <p>Conclusions</p> <p>The results of this study confirmed and expanded upon current knowledge about built and social environment influences on physical activity and health. That many residents reported changes in their behaviors since moving to the neighborhood permitted tentative inferences about the causal impact of built and social environments. Future research should exploit diverse methods to more fully understand how neighborhood contexts influence active living.</p

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome